ASCO Puts A Spotlight On CDK4/6 Category Ahead Of New Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Data to be presented at ASCO in June suggests Pfizer’s Ibrance has a good shot at maintaining a leadership position in the category as competitors Lilly and Novartis step closer to the market.
You may also be interested in...
Novartis CDK4/6 Profile Boosted But Challenge To Pfizer Rival Uncertain
Novartis' Phase III MONALEESA-2 trial shows that ribociclib plus letrozole has strong efficacy and an acceptable tolerability profile for first-line advanced HR+/HER2- breast cancer patients, but analysts say the results do not surpass those of Pfizer's first-to-market Ibrance plus letrozole in a similar setting.
Korea Green Light For Pfizer’s Novel Breast Cancer Drug
Pfizer's first-in-class breast cancer drug Ibrance is set to debut in South Korea following a regulatory approval and will offer a new option for the growing number of patients in the country.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.